Home›Trial›NCT04917887
🔬NCT04917887RECRUITING

Long-Term Follow-up Protocol

Study Summary

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

Conditions
Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
KRYS
Krystal Biotech
Gene Therapy
F30/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549418+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.